about
Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytesCurative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy.Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.New drug on the horizon for treating adenovirusA single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapyT cells for viral infections after allogeneic hematopoietic stem cell transplantChimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.Immunotherapy against cancer-related viruses.Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection.Immunotherapy for transplantation-associated viral infections.Transplantation: moving to the next level.Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes.Virus-Specific T Cells for the Immunocompromised Patient.Engineering haploidentical transplants.Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity.Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT.Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes.Clinical methods of cryopreservation for donor lymphocyte infusions vary in their ability to preserve functional T-cell subpopulations.A novel approach to improve immune effector responses post transplant by restoration of CCL21 expression.Cross-sectional analysis of CD8 T cell immunity to human herpesvirus 6B.
P2860
Q29393780-704A351D-C16E-4478-A1F0-FF6C19E3DDD1Q33647028-24D1B41E-2D19-43E1-A521-35D307DC9FD4Q34044757-4D88D5AB-9D04-4619-A8B5-DF69DA60210EQ36430680-7CE08C2A-DF58-4559-B298-A9D27551794FQ36900283-34787CBB-FE4F-4820-9880-06FEC0F52419Q36903202-FD84EC26-0935-4073-A2B0-D5DE98C34EC1Q37058107-0B6B6282-F9EA-4BA8-85C7-6B3489756179Q38435415-310A55B9-3CAC-440F-A25B-83566933ADE6Q38778924-7D44A729-5932-4D7C-B01B-1654A9C2B1C2Q38797660-2F2D669C-22BE-4075-91B0-F862698715E9Q38802522-E2EF90D7-A9B6-4E0C-A41B-24548F9A9443Q39382670-301506CA-B41C-44C4-9EFA-1E9A2829F65EQ40043395-C0FFFFFD-48F1-43FB-BBCF-9FA66EFAC16AQ40466464-99A640BE-DB7A-4395-B537-C3D8278F07CEQ42654381-016D45AE-018F-494F-8067-DE59308B7545Q45875855-D550F090-79AA-4A4F-B5F6-BAFD30DE97DCQ47152771-51330249-FB2E-456F-B5AE-E10362B9BF49Q47603836-05EC8C4C-4C7B-41FF-B8EB-A78C121FD545Q49798727-B863E853-5DD2-465F-994D-C1802BD785E3Q52774309-42516905-C44F-4C5C-9690-D87F986CA2CBQ55038717-0A772402-7BF9-49EB-8E82-E0BECC176F5FQ55342452-0EDA6E5C-E01A-4DA5-AF01-2AF8B88F688B
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Antiviral T-cell therapy
@ast
Antiviral T-cell therapy
@en
Antiviral T-cell therapy
@nl
type
label
Antiviral T-cell therapy
@ast
Antiviral T-cell therapy
@en
Antiviral T-cell therapy
@nl
prefLabel
Antiviral T-cell therapy
@ast
Antiviral T-cell therapy
@en
Antiviral T-cell therapy
@nl
P2093
P2860
P3181
P356
P1476
Antiviral T-cell therapy
@en
P2093
Ann M. Leen
Helen E. Heslop
Malcolm K. Brenner
P2860
P3181
P356
10.1111/IMR.12138
P407
P577
2014-03-01T00:00:00Z